

Application No. 10/519,419

REMARKS/ARGUMENTS

This is in response to the official action dated October 19, 2007. Reconsideration in view of the following is respectfully requested.

Claims 11-16 stand rejected under 35 USC 112. The examiner recognizes that the specification supports the teaching of antitumor effect against certain diseases. Claim 11-16 have been limited accordingly, and thus the rejection is overcome. The examiner also suggested that the claims be fashioned as a 'pharmaceutical', and the amendment has been adopted.


Claims 11-18 have been amended to follow the restriction of T to phenylalanine.

RECEIVED
CENTRAL FAX CENTER
JAN 04 2008

Application No. 10/519,419

Wherefore, allowance of all claims is earnestly solicited.

Respectfully submitted,
NORRIS MCLAUGHLIN & MARCUS, P.A.

By 
Bruce S. Londa
Reg. No. 33,531
875 Third Avenue
18th Floor
New York, New York 10022
Phone: (212) 808-0700
Fax: (212) 808-0844

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that the foregoing Amendment is being deposited with the Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450, on the date indicated below via facsimile transmission to (571) 273-8300 (6 pages):

Date: January 4, 2008

By 
Tina Manor